Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin

Hamauchi, Satoshi; Yokota, Tomoya; Mizumachi, Takatsugu; Onozawa, Yusuke; Ogawa, Hirofumi; Onoe, Tsuyoshi; Kamijo, Tomoyuki; Iida, Yoshiyuki; Nishimura, Tetsuo; Onitsuka, Tetsuro; Yasui, Hirofumi; Homma, Akihiro

Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin

Hamauchi, Satoshi; Yokota, Tomoya; Mizumachi, Takatsugu et al.

International journal of clinical oncology, 2019, 24(5), 468-475

Permalink : https://hdl.handle.net/2115/76534

このアイテムのアクセス数:1,226件（2026-08-27 07:52 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
Int J Clin Oncol_2019_24_468	pdf	261 KB	1,266

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/76534
タイトル	Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin
著者	Hamauchi, Satoshi ; Yokota, Tomoya ; Mizumachi, Takatsugu ; Onozawa, Yusuke ; Ogawa, Hirofumi ; Onoe, Tsuyoshi ; Kamijo, Tomoyuki ; Iida, Yoshiyuki ; Nishimura, Tetsuo ; Onitsuka, Tetsuro ; Yasui, Hirofumi ; Homma, Akihiro
著者名 Hamauchi, Satoshi
著者名 Yokota, Tomoya
e-Rad_Researcher 00507577 著者名 Mizumachi, Takatsugu
著者名 Onozawa, Yusuke
著者名 Ogawa, Hirofumi
著者名 Onoe, Tsuyoshi
著者名 Kamijo, Tomoyuki
著者名 Iida, Yoshiyuki
e-Rad_Researcher 30115498 著者名 Nishimura, Tetsuo
著者名 Onitsuka, Tetsuro
著者名 Yasui, Hirofumi
e-Rad_Researcher 30312359 著者名 Homma, Akihiro
言語	英語
キーワード	Head and neck cancer
	Carboplatin
	Cetuximab
	Chemoradiotherapy
発行日	2019-01-17
出版者	Springer
収録物名	International journal of clinical oncology
巻(号)	24(5)
ページ	468-475
抄録	Background : Locally advanced squamous cell carcinoma of the head and neck (LASCCHN) is usually treated with cisplatin (CDDP)-based chemoradiotherapy, except when patients are elderly or have renal, cardiac, or neurogenic dysfunction. This study compared the safety and efficacy of concurrent carboplatin (CBDCA) to cetuximab (Cmab) plus radiotherapy (RT) in patients ineligible for CDDP treatment. Methods : We retrospectively analyzed LASCCHN patients who received CBDCA plus RT (n = 29) or Cmab plus RT (n = 18) due to ineligibility for CDDP treatment at two Japanese institutions between August 2006 and December 2015. Results : Patients characteristics for CBDCA plus RT and Cmab plus RT were: median age, 74 and 75 years; 0-1 performance status, 90% and 100%; main primary tumor site, hypopharynx 52% (n = 15) and oropharynx 39% (n = 7); and stage IV, 90% (n = 26) and 50% (n = 9), respectively. With a median follow-up time of 60.0 months for CBDCA plus RT and 53.6 months for Cmab plus RT, 3-year locoregional control rates were 56% versus 58%, and median progression-free survival was 42.7 versus 11.6 months. CBDCA plus RT was associated with more grade 3/4 hematologic toxicities, including neutropenia and thrombocytopenia, whereas Cmab plus RT was associated with more grade 3/4 oral mucositis and radiation dermatitis. Conclusions : CBDCA or Cmab as a concurrent systemic therapy with RT is a possible treatment option for LASCCHN patients ineligible for CDDP treatment, although attention to hematological toxicity should be paid.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	This is a post-peer-review, pre-copyedit version of an article published in International Journal of Clinical Oncology. The final authenticated version is available online at: http://dx.doi.org/10.1007/s10147-018-01392-9
PISSN	1341-9625
関連情報	PMID 30656463
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1007/s10147-018-01392-9